Search
Now showing items 1-2 of 2
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.
(British Journal of Clinical Pharmacology, 2009)
AIMS
Efavirenz exhibits pharmacokinetic variability causing varied clinical response. The aim
was to develop an integrated population pharmacokinetic/pharmacogenetic model and
investigate the impact of genetic variations, ...
CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population
(Future Medicine Ltd: Pharmacogenomics, 2016)
To assess genotype effect on efavirenz (EFV) pharmacokinetics, treatment
outcomes and provide genotype-based EFV doses recommendations during for
tuberculosis (TB)-HIV-1 cotreatment. Materials & methods: EFV concentrations
from ...